GSK PLC closed 23.31% below its 52-week high of £18.24, which the company reached on May 16th.

Harvey Jones isn't having much fun playing the GSK share price game. The FTSE 100 pharmaceutical stock must work hard to make ...

Pharmaceutical giant GSK and the University of Oxford are creating a new cancer vaccine to prevent the disease from ...

Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...

GSK PLC closed 23.91% below its 52-week high of £18.24, which the company reached on May 16th.

Fifth Third Bancorp reduced its position in GSK plc (NYSE:GSK – Free Report) by 61.3% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 4,887 shares of the ...

Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

GSK plc has announced that new drug applications have been accepted for review by the China National Medical Products ...

Geneos Wealth Management Inc. purchased a new stake in shares of GSK plc (NYSE:GSK – Free Report) during the fourth quarter, ...

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.

GSK (GSK) stock in focus as its experimental drug depemokimab undergoes EU review for asthma and nasal polyps. Read more here ...

GSK and the University of Oxford have entered a new research partnership to launch an immuno-prevention programme to explore ...